Alpha-lipoic acid is an antioxidant used in Europe to promote liver and nerve health, and confer protective benefits against oxidative processes. Alpha-lipoic acid has been called the “universal” antioxidant because it boosts glutathione levels in cells already within a normal range and has potent antioxidant actions.128-130
Research has strongly implicated cellular oxidative damage caused by free radicals as a cause of many degenerative problems. What makes alpha-lipoic acid so effective as an antioxidant is its ability to quench free radicals in both aqueous and lipid environments. This means that the antioxidant activity of alpha-lipoic acid is working in the extra-cellular fluid and also within the cell. It also has metal chelating ability, helping the body rid itself of accumulated ingested toxins.131-134
Alpha-lipoic acid also is a cofactor for some of the key enzymes (alpha keto acid dehydrogenases) involved in generating energy from food and oxygen in mitochondria135-137 and thus plays a critical role in energy production within the cell’s mitochondria.127,135,136
One of the most beneficial effects of alpha-lipoic acid is its ability to regenerate other essential antioxidants such as vitamins C and E, coenzyme Q10, and glutathione, and the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx). The evidence is especially strong for the ability of DHLA (dihydrolipoic acid, a reduced form of alpha-lipoic acid) to recycle vitamin E. This is apparently achieved directly by quenching tocopherol radicals or indirectly by reducing vitamin C or increasing the levels of ubiquinol (a derivative of CoQ10) and glutathione, that, in turn, helps regenerate tissue levels of vitamin E.135,138-144
In clinical studies to date with alpha-lipoic acid, there have been no reported serious adverse side effects, even at high doses. Among the mild, reversible side effects found in some patients have been allergic skin reactions and possible hypoglycemia in diabetics. Please note that the R-lipoic acid provides a more biologically active form of lipoic acid than alpha-lipoic acid at only a slightly higher cost.
Supplement Facts |
Serving Size 1 capsule
|
Amount Per Serving |
Biotin
|
2500 mcg
|
Alpha-Lipoic Acid
|
250 mg
|
Other ingredients: rice flour, gelatin, vegetable stearate.
|
|
Non-GMO
|
Dosage and Use |
- Take one (1) capsule in the morning and one (1) capsule in the evening, preferably on an empty stomach, or as recommended by a healthcare practitioner.
|
Caution |
If you are taking glucose lowering medication, consult your healthcare provider before taking this product.
|
Warnings
- KEEP OUT OF REACH OF CHILDREN
- DO NOT EXCEED RECOMMENDED DOSE
- Do not purchase if outer seal is broken or damaged.
- When using nutritional supplements, please consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.
|
References
1. Ann N Y Acad Sci. 2004 Jun;1019:406-11.
2. Postepy Biochem. 2008;54(2):129-41.
3. Ann N Y Acad Sci. 2002 Apr;959:491-507.
4. Chang Gung Med J. 2009 Mar-Apr;32(2):113-32.
5. Exp Biol Med (Maywood). 2007 May;232(5):592-606.
6. Curr Aging Sci. 2008 Mar;1(1):10-21.
7. Biochim Biophys Acta. 2000 Jun 26;1486(1):1-17.
8. Acta Physiol Scand. 2003 Aug;178(4):385-90.
9. Int J Sports Med. 1998 May;19(4):231-44.
10. J Biol Chem. 2010. Jan 1;285:142-152.
11. Alt Med Rev. 2009; 14(3):268-77.
12. Entrez Gene: PARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha [ Homo sapiens ] GeneID: 10891.
13. Entrez Gene: CREBBP CREB binding protein [ Homo sapiens ] GeneID: 1387.
14. PLoS One. 2011;6(7):e21779. Epub 2011 Jul 21.
15. Hormones (Athens). 2008 Apr-Jun;7(2):123-32.
16. Protein Pept Lett. 2008;15(4):385-91.
17. J Alzheimers Dis. 2007 May;11(2):229-40.
18. Ann N Y Acad Sci. 2006 May;1067:369-74.
19. Sci Aging Knowledge Environ. 2005 May 4;2005(18):pe12.
20. Life Sci. 2007 Nov 30;81(23-24):1602-14.
21. J Nutr. 2006 Jun;136(6):1517-21.
22. J Neuroinflammation. 2008 Sep 25;5:41.
23. Immunology. 2005 Jul;115(3):375-87.
24. Am J Respir Crit Care Med. 2002 Mar 15;165(6):818-23.
25. Eur J Pharmacol. 2006 Jul 10;541(1-2):95-105.
26. Neurosci Lett. 2008 Dec 26;448(2):175-9.
27. Biochimie. 2011 Mar;93(3):506-12.
28. J Pharmacol Exp Ther. 2011 Sep;338(3):1013-22
29. Int J Neurosci. 2011 Jun;121(6):329-36.
30. Nat Med. 2003 Mar;9(3):294-9.
31. J Am Soc Nephrol. 2011 May;22(5):914-26.
32. Pharmacol Res. 2010 Jun;61(6):482-8.
33. Diabetes Care. 2006 Sep;29(9):2064-71.
34. Circ Heart Fail. 2010 Mar;3(2):294-305.
35. Acta Diabetol. 2001;38(3):135-8.
36. Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):371-7
37. Ann N Y Acad Sci. 2008 Apr;1126:288-90.
38. J Lipid Res. 2006 May; 47(5): 964-74
39. J Am Soc Nephrol. 2005 Jan;16(1):144-50.
40. Life Sci. 1988;43(21):1725-31.
41. Altern Med Rev. 2007 Dec;12(4):343-51.
42. FASEB J. 1999 Feb;13(2):411-8.
43. Antioxid Redox Signal. 2000 Fall;2(3):473-83.
44. FASEB J. 2001 Mar;15(3):700-6.
45. Arch Biochem Biophys. 2004 Mar 1;423(1):126-35.
46. Redox Rep. 2005;10(1):52-60.
47. Altern Med Rev. 2005 Dec;10(4):268-93.
48. Neurosci Lett. 1994 Jan 3;165(1-2):33-6.
49. Neurochem Res. 1995 Jan;20(1):1-9.
50. Rejuvenation Res. 2009 Dec;12(6):421-34.
51. Lancet. 1989 Mar 25;1(8639):642-5.
52. Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):511-7.
53. Age (Dordr). 2010 Sep;32(3):337-46.
54. Ageing Res Rev. 2011 Apr;10(2):238-52.
55. Eur J Neurosci. 2002 Sep;16(6):1015-24.
56. Nature. 2003 Apr 24;422(6934):832.
57. Connect Tissue Res. 1993;29(2):153-61.
58. Commun Integr Biol. 2011 Sep;4(5):627-9.
59. Cell Mol Life Sci. 2010 Oct;67(20):3435-47.
60. Zhonghua Yi Xue Za Zhi (Taipei). 2001 May;64(5):259-70.
61. Cardiovasc Drugs Ther. 2004 Nov;18(6):421-31.
62. J Cardiovasc Pharmacol Ther. 2006 Jun;11(2):119-28.
63. Biochem Biophys Res Commun. 2007 Nov 16;363(2):257-62.
64. J Clin Biochem Nutr. 2008 January; 42(1): 29–34.
65. FOOD Style. 2009;21:13(7)50-3.
66. J Nutr. 2006 Feb;136(2):390-6.
67. J Am Coll Nutr. 2001 Dec;20(6):591-8.
68. Free Radic Res. 2002 Apr;36(4):445-53.
69. Int J Biochem Cell Biol. 2005 Jun;37(6):1208-18.
70. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.
71. Neurobiol Dis. 2005 Apr;18(3):618-27.
72. J Mol Neurosci. 2006;28(2):125-41.
73. Brain Res Bull. 2006 Jun 15;70(1):22-32.
74. FEBS Lett. 1999 Jan 25;443(2):163-6.
75. Eur Heart J. 2006 Nov;27(22):2675-81.
76. Biofactors. 2005;25(1-4):137-45.
77. Mol Biotechnol. 2007 Sep;37(1):31-7.
78. Systemic CoQ level in animals: Part II. Unpublished study. Natreon, Inc.; 2007.
79. Pharmacologyonline. 2009;1:817-25.
80. Pharmacologyonline. 2009;2:690-8.
81. Electronic Journal of Biotechnology. 2008 Jul 15;11(3).
82. Ghosal S. Shilajit in Perspective. Alpha Science International Limited; 2006.
83. Kaneka Corp. Unpublished study. 2007.
84. Sci Total Environ. 1987 Apr;62:347-54.
85. Environ Sci Technol. 2002 Jul 15;36(14):3170-5.
86. Environ Sci Technol. 2002 May 1;36(9):1939-46.
87. Environ Sci Technol. 2009 Feb 1;43(3):878-83.
88. Regul Toxicol Pharmacol. 2007 Feb;47(1):19-28.
89. KANEKA CORP. Anti-fatigue effect in rats. Unpublished data, Kaneka Corp.
90. Exp Gerontol. 2006 Feb;41(2):130-40.
91. Ubiquinol has a higher bioavailability compared to ubiquinone. Unpublished data, Kaneka Corp.
92. Plasma levels of COQ10 for ubiquinol increased dose dependently. Unpublished data, Kaneka Corp.
93. LEF internal unpublished study 2006
94. Skin Pharmacol. 1994;7(5):278-84.
95. Circulation. 2008 Jan 22;117(3):421-8. Epub 2007 Dec 24.
96. Wien Klin Wochenschr. 2006 Mar;118(3-4):100-7.
97. Eur J Pharm Sci. 1999 Apr;8(1):57-65.
98. Free Radic Res. 2004 Oct;38(10):1083-92.
99. Biochem Mol Biol Int. 1998 Oct;46(3):585-95.
100. Am J Physiol. 1997 Jul;273(1 Pt 1):E185-E191.
101. Biochem Pharmacol. 1996 Feb 9;51(3):233-8.
102. J Mol Cell Cardiol. 1995 Sep;27(9):1895-903.
103. Z Naturforsch [C]. 1994 Sep-Oct;49(9-10):691-2.
104. Carlson DA, et al. Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects. Taylor & Francis Publishers; 2008:235-70.
105. Altern Med Rev. 2007; 12(4):343-51.
106. Int J Sport Nutr Exerc Metab.2008 Feb;18(1):19-36.
107. J Physiol. 2007 Jun 1;581(Pt 2):431-44.
108. Exp Physiol. 2008 Oct;93(10):1139-46.
109. Mol Aspects Med. 2004 Oct-Dec;25(5-6):533-49.
110. Clin Exp Pharmacol Physiol. 2006 Aug;33(8):725-33.
111. Neuropharmacology. 2008 Aug;55(2):223-9.
112. Neuropharmacology. 2006 Jun;50(8):917-23.
113. J Neurosci Res. 1991 Nov;30(3):555-9.
114. Neurochem Res. 1993 May;18(5):573-8.
115. Mol Cell Biochem.2003 Dec;254(1-2):227-34
116. J Int Soc Sports Nutr. 2007 Dec 3;4:22.
117. Int J Sport Nutr Exerc Metab. 2008 Feb;18(1):19-36.
118. Res Sports Med. 2009 Jan-Mar;17(1):1-16.
119. J Int Soc Sports Nutr. 2009 Apr 2;6:9.
120. Int J Vitam Nutr Res. 2009 May;79(3):131-41.
121. J Int Soc Sports Nutr. 2010 May 6;7:16.
122. Int J Vitam Nutr Res. 2010 Jan;80(1):12-23.
123. J Int Soc Sports Nutr. 2010 Oct 28;7:35.
124. Neurochem Res. 2009 Jun;34(6):1021-9.
125. Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Jun;28(3):113-20.
126. Mol Aspects Med. 2004 Oct-Dec;25(5-6):551-67.
127. Ann N Y Acad Sci. 2002 Apr;959:491-507.
128. J Appl Physiol. 1999 Apr;86(4):1191-6.
129. Chem Biol Interact. 2006 Nov 7;163(3):192-8.
130. Nutrition. 2007 Jan;23(1):76-80.
131. Am J Physiol Cell Physiol. 2007 Oct;293(4):C1395-403.
132. Pharmacol Ther. 2007 Jan;113(1):154-64.
133. Toxicol Lett. 2005 Dec 30;160(1):1-7.
134. Chem Biol Interact. 2004 Apr 15;147(3):259-71.
135. Chem Biol Interact. 2001 Nov 28;138(2):189-98.
136. Neurochem Res. 2007 Sep;32(9):1552-8
137. Drug Metab Rev. 1998 May;30(2):245-75.
138. Free Radic Biol Med. 1997;22(1-2):359-78.
139. Free Radic Biol Med. 2001 Jul 1;31(1):53-61.
140. Z Naturforsch [C]. 1998 Mar-Apr;53(3-4):250-3.
141. Nutrition. 2001 Oct;17(10):888-95.
142. Gen Pharmacol. 1997 Sep;29(3):315-31.
143. Biochim Biophys Acta 1988 Dec 16;963(3):558-61
144. Biochem Biophys Res Commun 1990 Jun 29;169(3):851-7.
|
Social Login